Darusentan Data to Be Presented at ISH 2006 -- Fukuoka, Japan
October 17 2006 - 4:00PM
Business Wire
Myogen, Inc. (Nasdaq: MYOG), a biopharmaceutical company focused on
the discovery, development and commercialization of small molecule
therapeutics for the treatment of cardiovascular disorders, today
announced that an abstract describing the effects of darusentan on
resistant hypertension (RHTN) has been selected for presentation at
the International Society of Hypertension (ISH) to be held Oct.
15-19, 2006, in Fukuoka, Japan. Lars Lindholm, M.D., will lead the
six-minute moderated poster presentation based on the abstract
titled �Darusentan for Resistant Hypertension.� The presentation is
scheduled for Wednesday, Oct. 18, 2006, at 1:35 p.m. at the Marine
Messe Fukuoka, 7-1 Okihama-machi, Hakata-ku, Fukuoka. Dr. Lindholm
is a professor at the Umea University Hospital in Sweden and a
member of the clinical advisory group for the darusentan
development program. Myogen has two product candidates in
late-stage clinical development: ambrisentan for the treatment of
patients with pulmonary arterial hypertension (PAH) and darusentan
for the treatment of patients with resistant hypertension. Myogen
and GlaxoSmithKline have entered into a global PAH collaboration in
which Myogen has marketing and distribution rights to
GlaxoSmithKline's Flolan� (epoprostenol sodium) for Injection in
the United States and GlaxoSmithKline has licensed ambrisentan from
Myogen for all territories outside of the United States, where
Myogen retains exclusive rights. Myogen also conducts a target and
drug discovery research program focused on the development of
disease-modifying drugs for the treatment of chronic heart failure
and related cardiovascular disorders. Please visit Myogen's website
at www.myogen.com. Safe Harbor Statement The anticipated
presentation will contain forward-looking statements that involve
significant risks and uncertainties, including those to be
discussed in the presentation and others that can be found in the
�Risk Factors� section of Myogen�s Form 10-K for the year ended
December 31, 2005 and Myogen�s periodic reports on Form 10-Q and
Form 8-K. Myogen does not undertake any obligation to update any
forward-looking statements contained in the anticipated
presentation as a result of new information, future events or
otherwise. The company cautions investors not to place undue
reliance on the forward-looking statements contained in this press
release or the presentation. No forward-looking statement can be
guaranteed and actual events and results may differ materially from
those projected. Myogen, Inc. (Nasdaq: MYOG), a biopharmaceutical
company focused on the discovery, development and commercialization
of small molecule therapeutics for the treatment of cardiovascular
disorders, today announced that an abstract describing the effects
of darusentan on resistant hypertension (RHTN) has been selected
for presentation at the International Society of Hypertension (ISH)
to be held Oct. 15-19, 2006, in Fukuoka, Japan. Lars Lindholm,
M.D., will lead the six-minute moderated poster presentation based
on the abstract titled "Darusentan for Resistant Hypertension." The
presentation is scheduled for Wednesday, Oct. 18, 2006, at 1:35
p.m. at the Marine Messe Fukuoka, 7-1 Okihama-machi, Hakata-ku,
Fukuoka. Dr. Lindholm is a professor at the Umea University
Hospital in Sweden and a member of the clinical advisory group for
the darusentan development program. Myogen has two product
candidates in late-stage clinical development: ambrisentan for the
treatment of patients with pulmonary arterial hypertension (PAH)
and darusentan for the treatment of patients with resistant
hypertension. Myogen and GlaxoSmithKline have entered into a global
PAH collaboration in which Myogen has marketing and distribution
rights to GlaxoSmithKline's Flolan(R) (epoprostenol sodium) for
Injection in the United States and GlaxoSmithKline has licensed
ambrisentan from Myogen for all territories outside of the United
States, where Myogen retains exclusive rights. Myogen also conducts
a target and drug discovery research program focused on the
development of disease-modifying drugs for the treatment of chronic
heart failure and related cardiovascular disorders. Please visit
Myogen's website at www.myogen.com. Safe Harbor Statement The
anticipated presentation will contain forward-looking statements
that involve significant risks and uncertainties, including those
to be discussed in the presentation and others that can be found in
the "Risk Factors" section of Myogen's Form 10-K for the year ended
December 31, 2005 and Myogen's periodic reports on Form 10-Q and
Form 8-K. Myogen does not undertake any obligation to update any
forward-looking statements contained in the anticipated
presentation as a result of new information, future events or
otherwise. The company cautions investors not to place undue
reliance on the forward-looking statements contained in this press
release or the presentation. No forward-looking statement can be
guaranteed and actual events and results may differ materially from
those projected.
Myogen (NASDAQ:MYOG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Myogen (NASDAQ:MYOG)
Historical Stock Chart
From Sep 2023 to Sep 2024